drugset / Trial / NCT00692952

Summary

A multicentric clinical trial in three Chinese Maternal and Child Hospitals was conducted to evaluate the efficacy, safety and acceptability of newly-developed vaginal contraceptive gel, the optimized benzalkonium chloride (BZK) gel containing 18mg BZK, with comparison to a currently marketed (in China)contraceptive gel LELEMI® containing 50mg Nonoxynol-9 (N-9).

Timeline

Start
2004-03
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BENZALKONIUM Small molecule 18 mg Other
Comparator Nonoxynol-9 Small molecule 50 mg Other

Indications

No indication recorded.